Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-29
2011-03-29
Andres, Janet L. (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C549S424000, C549S426000
Reexamination Certificate
active
07915433
ABSTRACT:
Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants.
REFERENCES:
patent: 5232929 (1993-08-01), Desai et al.
patent: 5300499 (1994-04-01), Chow
patent: 5344835 (1994-09-01), Alker et al.
patent: 0217286 (1987-04-01), None
patent: 0417698 (1991-03-01), None
patent: 9850534 (1998-11-01), None
patent: 9925686 (1998-11-01), None
Zhang et al., Bioorganic & Medicinal Chemistry Letters (2003), 13(9), pp. 1591-1595.
R.B. Kolhatkar et al., “Interaction of cis-(6-Benzhydrylpiperidin-3-y)benzylamine Analogues with Monoamine Transporters: Structure-Activity Relationship Study of Structurally Constrained 3,6-Disubstituted Piperidine Analogues of (2,2-Diphenylethy1)-[1-(4-fluorobenzyl)piperidin-4-ylmethyl]amine,” J. Med. Chem. 2003, 46, 2205-2215.
C. DeVries et al., “Heteroaromatic Analogs of 1-2[2-(diphenylmethoxy{ethyl]- and 1-[2[bis(4-fluorophenyl) methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as High-Affinity Dopamine Reuptake Inhibitors,” J. Med. Chem., 1997, 40, 705-716.
D. Matecka et al., Development of Novel, Potent, and Selective Dopamine Reuptake Inhibitors Through Alteration of the Piperazine Ring of 1-[2-(diphenylmethoxy)ethyl]- and 1[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909), J. Med. Chem., 1996, 39, 4704-4716.
R.B. Rothman, “Tight Binding Dopamine Reuptake Inhibitors as Cocaine Antagonists,” FEBS Lett., 1989, 257, 341-344.
J.R. Glowa et al., “The Effects of GBR 12909 on Responding of Rhesus Monkeys Maintained Under Schedules of Cocaine- and Food-Delivery,” NIDA. Res. Monogr., 1994, 141, 12.
A.K. Dutta et al., “Structure-Activity Relationship Studies of Novel 4[2-[Bis(4-fluorophenyl)methoxy] ethy]-1-(3-phenylpropyl)piperidine Analogs: Synthesis and Biological Evaluation of the Dopamine and Serotonin Transporter Sites,” J. Med. Chem., 1996, 39, 749-756.
A.K. Dutta et al., “Highly Selective, Novel Analogs of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine for the Dopamine Transporter: Effect of Different Aromatic Substitutions on their Affinity and Selectivity,” J. Med. Chem., 1997, 40, 35-43.
A.K. Dutta et al., “Potent and Selective Ligands for the Dopamine Transporter (DATE): Structure-Activity Relationship Studies of Novel 4-[2-(diphenylmethoxy)ethyl]-1-(3-phenylpropyl)piperidine Analogs,” J. Med. Chem., 1998, 41, 699-756.
Derwent Abstract, Eur. J. Nucl. Med., (1999), 26(4), 342-347, “In Vivo Imaging of Serotonin Transporters with [99mTc] TRODAT-1 in Nonhuman Primates” [AN 1999:196775].
A.K. Dutta et al., “Tolerance in the Replacement of the Benzhydrylic O Atom in 4-[2-(Diphenylmethoxy) ethyl]-1-benzylpiperidine Derivatives by an N Atom: Development of New-Generation Potent and Selective N-Analogue Molecules for the Dopamine Transporter,” J. Med. Chem., vol. 41, No. 17, pp. 3293-3297.
Database on STN CASDATA (Columbus, Ohio, USA) Abstract No. 132:119356, Hoepping et al., “Synthesis and biological evaluation of two novel DAT binding technetium complexes” Bioorg. Med. Chem. Lett. (1999) vol. 9, No. 22, pp. 3211-3216.
F. Ivy Carroll et al., “Cocaine and 3B-(4′-Substituted phenyl) tropane-2B-carboxylic Acid Ester and Amide Analogues. New High-Affinity and Selective Compounds for the Dopamine Transporter,” J. Med. Chem. 1995, 38, 379-388.
Amara, S. G., Kuhan, M. J. Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci, 1993, 16, 73-93.
Rudnick, G. Mechanisms of biogenic amine neurotransmitter transporters. In neurotransmitter transporters: Structure and function; Reith, M. E. A., Eds.; Human Press: Totowa, N J, second edition, 381-432, 2002.
Rudnick, G., Wall, S. C. The molecular mechanism of ectasy [3,4- methylendedioxymethamphetamine (MDMA)]-serotonin transporters are targets for MDMA induced serotonin release. Proc. Natl. Acad. Sci. USA, 1992, 89, 1817-1821.
Steele, T., Nichols, D., Yim, G. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamine into synaptosomes from different regions of rat brain. Biochem. Pharmacol. 1987, 36, 2297-2303.
Kuhar, M.J., Ritz, M.C., Boja, J.W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends. Neurosci. 1991, 14, 299-302.
Tatsumi, M., Groshan, K., Blakely, R. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 1997, 340, 249-258.
Richelson, E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J. Clin. Psychiatry. 2003, 64, 5-12.
M.J. Kuhar, “Neurotransmitter Uptake: A Tool in Identifying Neurotransmitter Specific Pathways,” Life Sci., 13, 1623-34, 1973.
M.E.A. Reith et al., “Strucural Requirements for Cocaine Congeners to Interact with Dopamine and Serotonin Uptake Sites in Mouse Brain and to Induced Stereotyped Behavior,” Biochem. Pharmacol., 1986, 35, 1123-1129.
M.C. Ritz et al., “Cocaine Inhibition of Ligand Binding at Dopamine, Norpinephrine and Serotonin Transporters: A Structure-Activity Study,” Life. Sci., 1990, 46, 635-645.
M.C. Ritz et al., “Cocaine Receptors on Dopamine Transporters are Related to Self-Administration of Cocaine,” Science, 1987, 237, 1219-1223.
B. Giros et al., “Hyperlocomotion and Indifference to Cocaine and Amphetamine in Mice Lacking the Dopamine Transporter,” Nature, 1996, 379, 606-612.
J.M. Maloteaux et al., Eur. J. Pharm., 1988, 156, 331-340.
H.B. Niznik et al., Arch. Biochem. Biophys., 1990, 276, 424-432.
K.M. Johnson, “Phencyclidine: Behavioral and Biochemical Evidence Supporting a Role for Dopamine,” Fed. Proc., 1983, 42, 2579-3583.
E.D. French et al., “Phencyclidine Binding Sites in the Nucleus Accumbens and Phencyclidine-Induced Hyperactivity are Decreased Following Legions of the Mesolimbic Dopamine System,” Eur. J. Pharmacol., 1985, 116, 1-9.
H. Kinemuchi et al., “The Neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its Relevance to Parkinson's Disease,” Neurochem. Int., 1987, 11, 359-373.
F.I. Carroll et al., “Cocaine Receptor: Biochemical Characterization and Structure-Activity Relationship of Cocaine Analogues at the Dopamine Transporter,” J. Med. Chem., 1992, 35, 969-981.
R.A. Millius et al., “Synthesis and Receptor Binding of N-substituted Tropane Derivatives,” “High Affinity Ligands for Cocaine Receptor,” J. Med. Chem., 1991, 34, 1728-1731.
I. Chaudieu et al., “Role of the Aromatic Group in the Inhibition of Phencyclidine Binding and Dopamine Uptake by PCP Analogs,” Pharmacol. Biochem. Behav., 1989, 32, 699-705.
J. Vignon et al., “[3H]N-[1(2-Benzo(b)thienyl)cyclohexyl]piperidine([3H]BTCP): A New Phencyclidine Analog Selective for the Dopamine Uptake Complex,” Eur. J. Pharmacol., 1988, 148, 427-436.
P.H. Anderson, “Biochemical and Pharmacological Characterization of [3H]GBR 12935 Binding in Vitro to Rat Striatal Membranes: Labeling of the Dopamine Uptake Complex,” J. Neurochem., 1987, 48, 1887-1896.
P.H. Anderson, “The Dopamine Uptake Inhibitor GBR 12909: Selectivity and Molecular Mechanism of Action,” Eur. J. Pharmacol., 1989, 166, 493-504.
Zhang, S., et al., “Design, Synthesis, and Preliminary SAR Study of 3- and 6-Side Chain Extended Tetrahydro-Pyran Analogues of cis- and trans-(6-benzhydryl-piperidin-3-yl)-benzylamine,” Bioorg. Med. Chem. 14, 3953-3966, 2006.
Zhang, S., et al., “Discovery of Novel tri-substituted Asymmetric Pyran Derivatives, (2S, 4R, 5R)-2-benzhydryl-5-benzylamino-tetrahyddropyran-4-ol, Exhibiting Stereospecific Manner,” J. Med. Chem. 48, 4962-4971, 2005.
English Abstract of JP Publ. No. 09-249566, Sep. 22, 1997 (2 pgs.).
Prof. Ar
Andres Janet L.
Brooks & Kushman P.C.
Covington Raymond
Wayne State University
LandOfFree
Tri-substituted 2-benzhydryl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tri-substituted 2-benzhydryl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tri-substituted 2-benzhydryl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2667244